The ADA 2022 was full of interesting symposia, updates on ongoing clinical trials, and a draft of an updated ADA-EASD consensus report. This year’s conference also put particular emphasis on weight management in the setting of type 2 diabetes as well as its associated cardiovascular and kidney comorbidities.

Join us as we speak to Professor Jennifer Green about her conference highlights, including:

- Draft ADA-EASD Consensus Report

- Results from the SURMOUNT-1 clinical trial of tirzepatide in people with obesity

- Further data for dual and triple incretin agonists and their potential future role

By completing this activity, you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References available here

Disclosures:

Prof. Jennifer Green declares the following financial relationships from the past 24 months:

Consultant: AstraZeneca, Bayer, Boehringer Ingelheim/Lilly, Hawthorne Effect/Omada (ended), Pfizer, NovoNordisk, Sanofi/Lexicon(ended), ICON/Vertex, and Anji.

Research support: Boehringer Ingelheim/Lilly, Merck, and Roche.

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Funding:

This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Eli Lilly has had no influence on the content of this education.